Real-world effectiveness and safety of apremilast in psoriasis at 52 weeks: a retrospective, observational, multicenter study by the Spanish Psoriasis Group

COMMENTED

Psoriasis

Apremilast in psoriasis - a prospective real-world study

J Eur Acad Dermatol Venereol.

Vujic I, Herman R, Sanlorenzo M, Posch C, Monshi B, Rappersberger K, Richter L

doi: 10.1111/jdv.14598.

Psoriasis

Secukinumab is effective in treatment of moderate to severe plaque psoriasis: Real-life effectiveness and safety from the PROSPECT study

J Eur Acad Dermatol Venereol.

Thaçi D, Körber A, von Kiedrowski R, Bachhuber T, Melzer N, Kasparek T, Duetting E, Kraehn-Senftleben G, Amon U, Augustin M

doi: 10.1111/jdv.15962.

PsoriasisFurther Publications Dermatology

Effectiveness and Safety of Apremilast in Biologic-naïve Patients With Moderate Psoriasis Treated in Routine Clinical Practice in Greece: the APRAISAL Study

J Eur Acad Dermatol Venereol

Ioannides D, Antonakopoulos N, Georgiou S, Chasapi V, Katsantonis I, Drosos A, Rigopoulos D, Antoniou C, Anastasiadis G, Bassukas I, Ioannidou D, Protopapa A, Neofotistou O, Krasagakis K, Aronis P, Papageorgiou M, Lazaridou E, Patsatsi A, Lefaki I, Roussaki-Schulze AV, Satra F, Anagnostopoulos Z, Papakonstantis M

doi: 10.1111/jdv.17392

Psoriasis

A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16-week real-life experience during the COVID-19 pandemic

J Eur Acad Dermatol Venereol

Hansel K, Zangrilli A, Bianchi L, Peris K, Chiricozzi A, Offidani A, Diotallevi F, Fargnoli MC, Esposito M, Amerio P, Gualdi G, Bianchi L, Stingeni L

doi: 10.1111/jdv.17003

Psoriasis

A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL)

J Eur Acad Dermatol Venereol.

Seneschal J, Lacour JP, Bewley A, Faurby M, Paul C, Pellacani G, De Simone C, Horne L, Sohrt A, Augustin M, Hammond E, Reich K

doi: 10.1111/jdv.16568.

Acne

Real-world effectiveness of adalimumab in patients with moderate to severe hidradenitis suppurativa: The 1-year SOLACE study

J Eur Acad Dermatol Venereol

Gulliver W, Alavi A, Wiseman MC, Gooderham MJ, Rao J, Alam MS, Papp KA, Desjardins O, Jean C

doi: 10.1111/jdv.17598

RECOMMENDED

Psoriasis

A prospective multi-center study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients

J Am Acad Dermatol.

Ortiz Salvador JM, Saneleuterio Temporal M, Magdaleno Tapial J, Manel VP, Conrad PM, Sahuquillo Torralba A, Mateu A, Pitarch G, Marí Ruiz JI, Mataix Díaz J, Montesinos Villaescusa E, Miralles Botella J, García Fernández L, Martorell Calatayud A, Belinchón Romero I, Sánchez Carazo JL, Pérez Ferriols A

doi: 10.1016/j.jaad.

Psoriasis

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study

J Am Acad Dermatol.

Bagel J, Duffin KC, Moore A, Ferris LK, Siu K, Steadman J, Kianifard F, Nyirady J, Lebwohl M

doi: 10.1016/j.jaad.2017.05.033.

Further Publications Dermatology

Treatment satisfaction, safety, and effectiveness of adding methotrexate to adalimumab in psoriasis patients responding sub-optimally to adalimumab in a real-world setting

Br J Dermatol

Papp KA, Gooderham MJ, Albrecht LE, Raymond MA, Lynde CW

doi: 10.1111/bjd.20885

Related content

Apremilast in psoriasis - a prospective real-world study

Secukinumab is effective in treatment of moderate to severe plaque psoriasis: Real-life effectiveness and safety from the PROSPECT study

Effectiveness and Safety of Apremilast in Biologic-naïve Patients With Moderate Psoriasis Treated in Routine Clinical Practice in Greece: the APRAISAL Study

A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16-week real-life experience during the COVID-19 pandemic

A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL)

Real-world effectiveness of adalimumab in patients with moderate to severe hidradenitis suppurativa: The 1-year SOLACE study

A prospective multi-center study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study

Treatment satisfaction, safety, and effectiveness of adding methotrexate to adalimumab in psoriasis patients responding sub-optimally to adalimumab in a real-world setting